- By ICR Secretariat
- Posted Thursday, December 1, 2022
FDA grants speedy review to Sarepta’s Duchenne gene therapy
https://www.biopharmadive.com/news/fda-priority-review-sarepta-duchenne-gene-therapy/637366/
The Food and Drug Administration has started the first regulatory review of a gene therapy for Duchenne muscular dystrophy, the treatment’s developer, Sarepta Therapeutics, announced on Monday.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- 10 clinical trials to watch in the first half of 2023 19/01/2023 03:56 PM
- 'The Top Line': FDA's stance on cancer drug approval, plus this week's headlines 19/01/2023 03:55 PM
- 5 questions facing gene therapy in 2023 19/01/2023 03:53 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org